Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN023 in rabies post-exposure prophylaxis in children
NCT07342257Phase 1Completed
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zamerovimab + mazorelvimab in rabies (3 arms), sponsored by Xingmeng Biopharmaceutical. Primary endpoints: Adverse Drug Reactions at 42 days and Serious Adverse Events at 126 days. Started Nov 2024; status: completed.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on NCT07342257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342257.